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Normal Lewis rat serum contains antibodies (IgM 
> IgG) that bind to hamster leukocytes and endo-
thelial cells. Transplantation of either the heart or 
liver from hamster rat results in release of ham-
ster hematolymphoid cellsfrom the graft, which 
lodge in the recipient spleen (cell migration), 
where recipient T- and B-cell populations initiate 
DNA synthesis within one day. There is marked 
stimulation of splenic IgM++(brlgh')/IgD+(duU) B 
cells in the marginal zone and red pulp, which 
accountfor 48% of the total splenic blast cell pop-
ulation by 4 days after liver transplantation. 
CD4 + predominant T-cell proliferation in the 
splenic periarterial lymphatic sheath and para-
cortex of peripheral lymph nodes occurs almost 
simultaneously. The effector phase of rejection in 
cardiac recipients is dominated by complement-
fixing IgM antibodies, which increase daily and 
result in graft destruction in 3 to 4 days, even in 
animals treated with FK506. In liver recipients, 
combined antibody and cellular rejection, asso-
ciated with graft infiltration by OX8+ natural 
killer, andfewer W3/25 + (CD4) lymphocytes, are 
responsible for graft failure in untreated recipi-
ents at 6 to 7 days. FK506 inhibits the T-cell re-
sponse in liver recipients and significantly pro-
longs graft survival, but does not prevent the rise 
or deposition of IgM antibodies in the graft. How-
ever, a single injection of cyclophosphamide 10 
days before transplantation effectively depletes 
the splenic IgM++(brlght)/IgD+(dull) cells and in 
combination with FK506, results in 100% survival 
of both cardiac and hepatic xenografts for more 
than 60 days. Although extrapolation of morpho-
logical findings to functional significance is 
fraught with potential problems, we propose the 
following mechanisms of xenograft rejection. The 
reaction initially appears to involve primitive 
host defense mechanisms, including an IgM-
producing subpopulation of splenic B cells and 
natural killer cells. Based on the reaction and dis-
tribution of OX8+ and W3/25+ cells, antibody-
dependent cell cytotoxicity and delayed-type hy-
persensitivity responses seem worthy of further 
investigation as possible effector mechanisms. Ef-
fective control of xenograft rejection is likely to 
require a dual pharmaceutical approach, one to 
contain T-cell immunity and another to blunt the 
primitive B-cell response. (Am J Pathol 1993, 
143:85-98) 
Restrictions imposed by the limited number of suit-
able human donor organs has recently curtailed the 
growth of transplantation as a readily available form 
of therapy. Attempts to use nonhuman primates as 
donors for human recipients in the 1960's were aban-
doned because of formidable immunological barri-
ers, lack of effective immunosuppressive therapy, 
and the emergence of hemodialysis as an alternative 
treatment 1- 2 for endstage renal disease. 
With the recent introduction of FK506, transplan-
tation of allografts once thought too difficult to at-
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tempt, such as the small intestine, has become pos-
sible 3 Although in xenotransplantation the major 
immunological barrier is thought to be humoral,4-7 re-
cent slJccess with FK506 as monotherapy in the 
hamster-to-rat hepatic xenograft model is quite prom-
ising B In addition, the combination of FK506 or cy-
closporine with "anti-proliferative" agents has re-
sulted in excellent cardiac and hepatic xenograft 
survival in the hamster-to-rat model 9 ,10 
Part of the success of FK506 in hepatic xenotrans-
plantation can be attributed to the liver's natural re-
sistance to antibody-mediated rejection.11 On the 
other hand, survival of a graft with an arterial-only af-
ferent vasculature, such as the heart, is not prolonged 
by FK506, except when combined with splenec-
tomy12 or drugs that inhibitthe antibody response,9,10 
The importance of antibodies as primary mediators 
of graft damage, and of the spleen 12-15 in the devel-
opment of xenograft effector response notwithstand-
ing, there are conflicting results regarding the im-
mune mechanisms of xenograft rejection,16 This is 
particularly true with studies based on in vitro anal-
yses, 16 and in vivo studies are in need of further in-
vestigation. 17 
The goals of this study are two-fold: 1) to delineate 
the morphological correlates of the initiation and ef-
fector phases of xenograft rejection in vivo, with and 
without therapy; and 2) to define more accurately the 
role of the spleen. Our experiments were primarily 
with the liver, because this organ's natural resistance 
to antibody-mediated damage and natural tolerizing 
influences 18, 19 make it an attractive target for clinical 
trials of xenotransplantation, However, the hetero-
topic heart transplant model also was studied, be-
cause it exemplified the susceptible end of the 
antibody-sensitive spectrum, 
Materials and Methods 
Operative Procedures 
Male LVG hamsters (100-150 g) and male Lewis 
(LEW) rats (240-280 g) served as donors and recip-
ients, respectively. Orthotopic liver transplantation 
was performed according to the cuff technique of 
Kamada and Calne,20 Donor cholecystectomy was 
carried out at the time of grafting and the prepara-
tion lacked anastomosis of the hepatic artery. Het-
erotopic heart transplantation was performed by a 
microsurgical technique as described by Ono and 
Lindsey.21 
Experimental Design 
In the first set of experiments, a comparison was 
made of the histo- and immunopathology of rejec-
tion between FK506-treated and -untreated liver 
and cardiac xenograft recipients in the LVG hamster 
to LEW rat transplantation model. Untreated liver 
xenograft recipients were sacrificed on days 1 
through 5 (n = 3 on each day), and untreated car-
diac xenograft recipients were sacrificed on days 2, 
3, and 4 (n = 1 on each day), The treated liver xe-
nograft recipients were given FK506 (1.0 mg/kg/ 
day), started on the day of transplantation and con-
tinued until the rats were sacrificed for study on 
days 3, 4, and 5 (n = 3 on each day), 
In a second series of experiments, the effect of 
therapy on graft survival was studied, A single 500 
mg/m2 (-80 mg/kg) dose of cyclophosphamide 
(CYP) previously shown to deplete marginal zone B 
cells in the rat,22 was given 10 days before the 
transplantation of heart or liver xenograft. At the 
time of transplantation, heart graft recipients re-
ceived 2 mg/kg/day of FK506 for 15 days, 1 mg/kg/ 
day for days 15 to 30, and 0.5 mg/kg every other 
day until day 100. Liver graft recipients received 1 
mg/kg/day of FK506 for 30 days and 0.5 mg/kg/day 
every other day up to day 100, Animals treated only 
with that same dose of FK506 and untreated graft 
recipients were included as controls, The causes of 
graft failure and/or death were confirmed histologi-
cally, 
Tissue Triage and Immunoperoxidase 
Studies 
A complete autopsy was done, and tissue from all 
organs was frozen in optimum cold temperature 
compound (Tissue-Tek, Ames Division, Miles Labo-
ratories, Inc., Elkhart, IN) for immunoperoxidase 
studies and formalin-fixed for routine histological 
examination, For immunostaining of the graft and 
recipient spleen, the following panel of monoclonal 
antibodies (MAbs) were used: OX8 (1 :150; non-
helper subset, Sera-lab), W3/25 (1: 1 00; T helper/ 
inducer and subsets of other accessory cells, Sera-
lab), OX33 (1: 1 00; B-cell marker, Serotec, 
Indianapolis, IN), MCA 190 (1 :50; mouse anti-rat 
IgD heavy chain, Serotec), IgMbiO (1 :75; anti-rat 
IgM-biotinylated, Accurate) and NKR-P1 (1 :100; 
natural killer cell specific marker, courtesy of Dr, Wil-
liam Chambers, Pittsburgh Cancer Institute, Pitts-
burgh, PAl, 
A standard avidin-biotin-peroxidase complex 
method was used as previously described, 23 A 
Shandon Cadenza automated immunostainer was 
used for the actual staining (Shandon Scientific Lim-
ited, Cheshire, England). 
Cell Trafficking Studies 
Donor hamster cells were identified with polyclonal 
fluorescein isocyanate (FITC)-conjugated rabbit 
anti-hamster lymphocyte antibody (Inter-Cell Tech-
nologies, Inc., Hopewell, NJ). The neat antibody 
was diluted 1: 1 0 and then absorbed with LEW (re-
Cipient) white blood cells from the spleen and 
lymph nodes to remove crossreactive antibodies. 
The LEW cells were prepared on a Ficoll gradient 
and washed (three times) with RPMI 1640 culture 
medium (GIBCO, Grand Island, NY) and pelleted. 
5.0 x 106 cells were then resuspended in 500 ~f of 
the diluted antibody and incubated for 15 minutes. 
The cells were then pelleted (1500 rpm for 10 min-
utes), the supernatant collected, and the entire pro-
cedure repeated twice. 
Before staining, the nonspecific protein-binding 
activity in the tissue sections was inhibited by incu-
bation with protein-blocking agent (Lipshaw Co., 
Detroit, MI) for 20 minutes. The absorbed antibody 
was then applied for 40 minutes, followed by two (5 
minute) washes in phosphate-buffered sal ine (PBS) 
and mounting in anti-fade (Oncor, Gaithersburg, 
MD). Specificity of the absorbed antibody was con-
firmed by using normal LEW rat and LVG hamster 
spleens and livers as controls. 
Identification of LEW rat cells was achieved by 
using the MAb L-21-6, which reacts with the invari-
ant chain of the LEW rat, but not with that of the 
hamster.24 Normal LEW rat and LVG hamster 
spleens and livers were used as controls. 
Immunofluorescence Studies 
An indirect immunofluorescent assay was used to 
evaluate the tissue-binding activity of preformed 
anti-hamster antibodies in the LEW rat. Cryostat 
sections of normal LVG hamster heart and liver 
were incubated with protein blocking agent for 20 
minutes followed by incubation with undiluted nor-
mal LEW rat serum for 30 minutes. The sections 
were washed twice in PBS, incubated with goat 
anti-rat IgG or IgM, washed twice in PBS and 
mounted in anti-fade (Oncor). Normal hamster sera 
were substituted for the rat sera as a negative con-
trol. 
A direct immunofluorescent assay was used to 
detect IgM, IgG, and C3 deposition in the xe-
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nografts and IgM+ and IgG+ cells in the recipient 
spleen. Cryostat sections of the grafts and recipient 
spleen were incubated with FITC-conjugated goat 
anti-rat IgG (heavy and light) (1 :25, Jackson Immu-
noResearch Labs., Inc., West Grove, PAl, IgM 
(1:25, Jackson), or C3 (1:25, Cappel Research 
Products, Durham, NC), for 30 minutes, washed in 
PBS twice, and mounted in anti-fade (Oncor). The 
above antibodies were absorbed with 10% heat-
inactivated normal hamster serum for 45 minutes 
before use. Normal rat spleen or lymph nodes 
served as the positive control. All of the above 
stains were reviewed on a Nikon fluorescent micro-
scope. 
Complement-Dependent Cytotoxicity 
Complement-fixing Iymphocytotoxic antibodies 
were measured in five normal LEW rats. Briefly, 30 
minutes after incubation of the rat serum and com-
plement (37 C, 95% O2, 5% CO2) with hamster 
lymph node cells (5 x 106 /ml), the percentage of 
cells stained with trypan blue was calculated. The 
Iymphocytotoxic antibody titer was defined as the 
highest serum dilution with more than 25% cell lysis. 
Baby rabbit serum (Accurate) diluted 1: 1 0 served 
as the source of complement. Normal hamster se-
rum served as the negative control. Hyperimmune 
serum was used as the positive control. 
Proliferative Activity 
To determine the sites of recipient lymphoid activa-
tion, as measured by proliferation, a mitotic index 
analysis was performed on each of the animals, as 
previously described.23 Briefly, metaphase mitotic 
figures were counted in a standardized area of an 
H&E-stained section of the recipient spleen. In ad-
dition, tissues from one animal at each time point 
were stained with anti-proliferating cell nuclear anti-
gen (PCNA) (Signet Laboratories, Inc., Dedham, 
MA) as previously described,25 
Flow Cytometric Analysis 
The spleens from FK506-treated (n = 3) and 
-untreated (n = 3) hepatic xenograft recipients sac-
rificed on days 4 and 5 were used to prepare a 
single-cell suspension of splenocytes for pheno-
typic analysis in cold RPMI 1640. Viability, deter-
mined by trypan blue exclusion, was always >90%, 
Single-color staining was carried out using the 
same unconjugated primary antibodies as used for 
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immunostaining above (OX8, 1 :150; W3/25, 1 :100; 
OX33, 1: 1 00; NKR-P1, 1 :500), with a rat anti-mouse 
IgG FITC (Accurate) secondary antibody. Two-color 
staining was done using goat anti-rat IgM F(abh' 
phycoerythrin 1:100 (Jackson) and IgD-FITC 1 :50 
(Serotec), incubated separately. The cell suspen-
sion was washed twice with Hanks' balanced salt 
solution (HBSS) (GIBCO) containing 1.0% sodium 
azide (St. Louis, MO) and 1.0% bovine serum albu-
min (GIBCO) before fixation in 1.0% paraformalde-
hyde. Samples were then stored at 4 C until analy-
sis. Mouse IgG 1 FITC (Dako Corp., Carpinteria, 
CAl, (Dako), and goat anti-rat F(abh' phycoerythrin 
mouse IgG 1 (Jackson) were used as negative con-
trols. 
To determine binding of rat IgG or IgM to hamster 
lymphoid cells, diluted (1: 1 00 in HBSS with 1 % bo-
vine serum albumin and 0.1 % sodium nitrate) nor-
mal LEW rat serum was incubated with hamster 
lymph node cells for 45 minutes at 4 C. Diluted (1: 
100) hamster serum or buffer alone served as con-
trols. After incubation, the cells were washed and 
FITC-conjugated goat anti-rat IgG (Accurate) or IgM 
antibody (1 :75 dilution) was added and the cells 
were incubated for another 30 minutes at 4 C. Cells 
were then washed twice and fixed in 1 % paraform-
aldehyde. 
Ten thousand cells from each sample were ana-
lyzed on a flow cytometer (FACS II, Becton Dickin-
son, Mountain View, CAl Splenocytes from a nor-
mal LEW rat served as a baseline control. 
Results 
Preformed Antibody Analysis 
Lymphocytotoxic crossmatch studies were per-
formed in five normal LEW rats before transplanta-
tion. The titer of anti-hamster cytotoxic antibodies 
present varied between 1:16 (n = 2) to 1:32 (n = 
3). Flow cytometric studies using normal hamster 
lymph node cells as targets and normal LEW rat se-
rum as the primary antibody revealed binding of 
IgM » IgG. Lastly, serum from normal LEW rats 
bound to hamster endothelial cells (large vessels 
and microvasculature) in the heart and liver, with 
IgM much greater than IgG, using the indirect im-
munofluorescent assay. We could not, however, as-
certain whether the binding in tissue sections was 
directed at surface or cytoplasmic constituents. 
Routine and Immunopathology of Cardiac 
and Hepatic Xenograft Rejection 
Cardiac Grafts 
Untreated recipients showed classical features of 
humoral rejection, which gradually developed over 
the first 3 days. There was progressive platelet, fi-
brin, and neutrophil plugging of the microvascula-
ture and margination in larger vessels, which 
showed endothelial cell hypertrophy and focal den-
udation. The process culminated on days 3 to 4 
with widespread hemorrhagic necrosis (Figure 1). 
No mononuclear infiltrates were seen in any of the 
samples. Therefore, immunoperoxidase stains for 
infiltrating mononuclear cell phenotypes were nega-
tive, including L-21-6, used to identify class II 
MHC + recipient mononuclear cells. However, immu-
nofluorescence studies showed daily increasing 
IgM » IgG and C3 deposits in both larger vessels 
and diffusely throughout the microvasculature (Fig-
ure 1). FK506 did not significantly prolong graft sur-
vival or change the routine histologic or immunoflu-
orescence findings. 
Hepatic Grafts 
In the untreated recipients, the findings on day 1 
were limited to focal platelet plugs, which were lo-
cated in portal veins and scattered throughout the 
sinusoids. IgM » IgG and C3 deposits were 
present on the endothelium of the microvasculature 
and larger vessels. 
Day 2 was marked by the appearance of spotty 
hepatocyte necrosis with polymorphonuclear cell 
sludging in the peribiliary vascular plexus, occa-
sional sinusoidal lymphocytes, a minimal mixed por-
tal cellular infiltrate, and partially degranulated mast 
cells in the hilum. The phenotypic composition of 
the portal and scattered sinusoidal infiltrate con-
sisted largely of OX8+ cells with fewer NKR-P1 + 
and W3/25 , cells. IgM+ cells were rare, and no 
OX33+ or IgO+ cells were present. 
The findings on day 3 (Figure 2) resembled an 
escalated version of day 2 with a mild-to-
moderately mixed portal infiltrate consisting of a 
significant increase of OX8' cells and a slight in-
crease of NKR-P1 + cells. Endothelial cell damage 
worsened and platelet/fibrin thrombi were scattered 
throughout the vasculature. Occasional IgO+ cells 
also appeared in the triads. 
By day 4, neutrophils and mast cells were less 
numerous, but a striking sinusoidal mononuclear in-
filtrate appeared, consisting predominantly of OX8+ 
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Figure 1. Ca rdiac g rafts uniformly fa iled In 3 10 4 days because of pure b umoral rejeclion , wilh (A), plaleiel-jibrln thrombi 111 Ihe m icrovascula-
ture (arrow), widespread hemorrbaglc necrosis (a: H&E, x250) and (8), marked deposlNon of anli-ba msler IgM antibodies (left; a nti-rat IgM IF, 
x JOO). IgC depositior! was nlLlcb less (right a nti-raIIgC; X JOO). 
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Figure 2. Liver grafts in un/rea/ed rl!Cipien/s developed m(xed humoral and cellula r reject ion (A; /-/&£, X 100), with (B) marked deposition of IgM 
(lett, anti-rat JgM IF, X 100) and much less IgC (right: aI/Ii-rat IgC IF; X 100). No/e tbe pO/1al a nd sinllsoidal mononuclear infiltrates. 
cells with fewer NKR-P1 + and W3/25+ cells, and 
only occasional OX33+ and Igo+ lymphocytes. 
OX8+, W3/25+, and Igo+ cells were also increased 
in the triads. Congestion, bile duct proliferation, and 
small infarcts also appeared. All of these findings 
worsened on day 5, and were accompanied by 
large areas of hemorrhagic necrosis, presaging 
graft failure. By this time the daily increasing depos-
its of IgM » IgG and C3 on the endothelium, bile 
ducts, and hepatocytes had become massive. Ob-
servations after day 5 were not systematically re-
corded because of the extensive necrosis. 
In the FK506-treated animals sacrificed for histo-
logical examination during the first 5 days, the rou-
tine and immunopathological changes were qualita-
tively similar, but much less severe than described 
above. Scattered platelet/fibrin thrombi and a mild 
portal and sinusoidal inflammatory infiltrate ap-
peared dUring the first 3 days, which was phenotyp-
ically similar to that seen in the untreated recipients. 
However, by day 5 the overall inflammatory infiltrate 
was noticeably less severe in the FK506-treated 
rats, and qualitatively different. The relative amount 
of OX33+ and W3/25 + cells was increased, 
whereas the OX8+ cells were reduced. Despite the 
noticeable decrease in the cellular infiltrate, there 
was only a slight decrease in the IgM » IgG and 
C3 deposits, which were easily detectable in the 
same distribution as in the untreated recipients. 
Splenic Response 
The splenic proliferative response was quantified 
and the phenotypic composition of the splenocytes 
was recorded. Proliferation evoked by the hepatic 
xenografts (day 4 peak) was significantly higher 
than that evoked by the cardiac graphs (day 3 
peak) in untreated recipients (Figure 3). However, 
FK506 therapy alone significantly blunted the prolif-
eration associated with liver transplantation. Never-
theless, increased mitotic activity remained, espe-
cially in the red pulp. The localization and the 
phenotypic profile of the responding splenocyte 
populations is presented in detail below. 
Cardiac Graft Recipients 
Blast transformation and mitotic activity of cells in 
the red pulp (lgM++), marginal zone (MZ) (lgM++I 
Igo-), and at the MZ/periarterial lymphatic sheath 
(PALS) interface (W3/25+ and NKR-P1 +) was evi-
dent within 2 days after transplantation. By days 3 
and 4, clusters of mitotically active surface IgM' 
(slgM) plasmablasts and cytoplasmic IgM+ (clgM) 
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Figure 3. Splenic proliferative index of untreated cardiac (0) and 
liver~F and FK506 treated liver (e) xenograft recipients. tbe values 
shown represent the mean of three rats at each time point, exceptIor 
tbe cardiac recipients (n = 1). and tbe error bars are the standard 
deviation. 
plasma cells with PCNA labeling of >60% ap-
peared in the red pulp. IgG+ cells constituted a dis-
tinct minority population. 
Hepatic Graft Recipients 
Marked blast transformation, mitotic activity, and 
PCNA labeling were seen in the IgM+ + /Igo+ cells 
in the MZ (Figure 4), and in small clusters of NKR-
P1 + and W3/25+ cells at the MZ-PALS interface, 
one day after transplantation. 
This pattern was accentuated on day 2 when, in 
addition, slgM++ blasts with a PCNA labeling per-
centage >70%, and clgM+ plasma cells began to 
fill the red pulp. By days 2 to 3, the MZ had been 
depleted and blast transformation of the PALS was 
particularly brisk (Figure 4), resulting on day 4 in al-
most total replacement of the PALS by large, mitoti-
cally active cells. Meanwhile, the red pulp became 
engorged with the IgM+ cells mentioned above 
(Figure 5). Surprisingly few IgG+ cells were noted in 
the spleen. 
FK506 muted the blast transformation of the 
PALS and the proliferative response to hepatic 
grafts described above. A well defined MZ and 
PALS were still easily discernable at 5 days. How-
ever, the population of mitotically active IgM+ cells 
with a PCNA labeling of >60% still expanded the 
red pulp, but to a lesser degree than in the un-
treated animals. 
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Flow Cytometry 
Analyses were performed on days 4 and 5 after 
hepatic transplantation , which corresponded to the 
peak proliferative response. Compared with normal 
controls , recipients of hepatic xenografts developed 
a population of cells with a larger forward and wide-
angle scatter, approximating the blast cell popula-
tion observed histologically (Figure 6) . The blast 
population accounted for 34% of the total in un-
treated reCipients and 18% in treated recipients . 
The phenotypic composition of the blasts in both 
groups are shown in Table 1. 
The overall proportion of blasts as well as the 
percent of IgM++/lgO+ cells decreased in the 
FK506-treated recipients. However, up to 25% of 
the blasts in the treated population still consisted of 
IgM++/lgO+ cells. 
Peripheral Lymph Node Response 
Blast transformation and mitotic activity was evi-
dent in the paracortex and interfoll icular regions of 
untreated cardiac and hepatic xenograft recipients 
within one day after transplantation . This response 
continued to expand, and by days 3 to 4, germinal 
centers appeared and the paracortex was markedly 
Figure 4. A: The MZ of normal rat spleen consists largely of slgAr' , B 
cells, many of which show light PCNA nllclear sWin ing (anti-rat IgM; 
X 250). B: one day after hepatic transplantation ma rked hy blast tra ns-
formation, mitotic activity, and a greater number of MZ cells showed 
"' Iense PCNA nuclear sWining (a; anli-PCNA 'PEX, X 250). C: By day 
3. the red pulp (RP) became engorged with clusters of mitotically active 
Igfrr see (FIgure 5) plasmablasls, and germinal cenler.; appeared. The 
proliferative activily of Ihese populations was confirmed by nuclear 
PCNA labeling (anli-PCNA immunoperoxidase wilh hematoxylin coun-
terstain; X 400) . . 
enlarged by a mixture of W3/25+ and slgM+ cells, 
whereas the medulla was engorged with slgM+ 
plasmablasts and clgM+ plasma cells . 
The lymph node response in the FK506-treated 
reCipients was markedly diminished. Little if any 
blast transformation in the paracortex was noted, 
and engorgement of the medulla with IgM+ cells 
and germinal center format ion was almost com-
pletely inhibited. 
Cell Migration Studies 
Recipient spleens were examined 1, 3, and 5 
days after hepatic xenografting, and 2 days after 
cardiac transplantation . Hamster cells were present 
in the splenic PALS and most numerous (approxi-
mately five to six cell s/PALS cross-section) on day 1 
after hepatic transplantation (Figure 7) In the un-
treated cardiac and liver graft reCipients on days 3 
and 5, hamster cells were difficult to find , or absent. 
Effects of Therapy on Survival 
Two animals treated with a single dose of CYP were 
sacrificed for splenic histology and flow cytometric 
analysis 10 days after injection . There was striking 
Figure 5. The celts jilting the splen ic red p ulp of liuer xe' fOgrafi recip-
ienlS 3 days afier ITampla lltaiion co nsisted mostly 0/ 11jI1f' cells (top: 
emU-Tat IgM; X 40) with mCiny fewer IgG" cells (bottom: anli-Tal I.QC 
IF; X 40) . "{be unstnined areas in the top photomicrograph Clre the pe-
riarlenallympha tic sheaths 
depletion of the IgM++/lgO+ cells in the marginal 
zone, which represented only 3% of the splenocyte 
population , in comparison to 12% in normal con-
trols. The percentage of other splenic lymphoid 
cells (Ox8+, W3/25 + NKR-P1 +, IgO+ +/lgM +) in 
CYP-treated rats were all within normal limits, con-
sistent with the observations of Kumararatne et al22 
(Figure 8) 
Heart and liver graft survival after the various 
forms of therapy is shown in Table 2. FK506 therapy 
alone did not significantly prolong survival of the 
cardiac xenografts, which failed, as in the untreated 
controls, because of humoral rejection . However, 
the CYP therapy alone increased survival from 3 to 
6 days, at which time the failed grafts showed a 
dense cellular infiltrate, typical of cellular rejection . 
The combination of FK506 and CYP resulted in ex-
cellent graft survival. 
In contrast, FK506 therapy alone resulted in a 
significant prolongation of liver xenograft survival 
(Table 2) Histologic examination of the failed grafts 
revealed changes of biliary obstruction and grossly, 
"bilomas" were noted . CYP therapy alone did not 
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enhance liver graft survival , but combination of the 
two drugs yielded excellent results. 
Discussion 
Humoral effector mechanisms appear to be respon-
sible for cardiac xenograft failure and cause signifi-
cant hepatic xenograft injury in this model. The re-
sponse appears immediately after transplantation 
and is dominated by complement-fixing IgM anti-
bodies, consistent with the studies of Hasan et al 'o 
and Platt et al .26 Although we were unable to deter-
mine with certainty whether the predominant IgM or 
IgG fraction was the more destructive, Platt and oth-
ers have shown that the IgM antibodies4-7,l o.26 are 
largely responsible for graft damage. 
The deposition of antibodies is quickly followed in 
the liver grafts by a cellular infiltrate enriched in 
OX19+/0X8+(CD8) cells , with fewer NKR-P1 + (nat-
ural killer) cells, in the sinusoids and portal tracts , 
the sites of antibody deposition . This is different 
from liver allograft rejection, where the initial infil-
trate is portal or perivenular 23 Lastly, portal and 
perivenular W3/25 + cells appear. Although we can 
only speculate as to the functional significance of 
the observations above, the role of antibody-
dependent cellular cytotoxicity in xenograft rejec-
tion is certainly worthy of further investigation . 
At least one explanation for the importance of the 
spleen in xenograft rejection is based on the 
marked stimulation of IgM+ +/lgD + B cells , which in 
the rat are preferentially localized in, and thought 
to be confined to, the MZ and red .pulp of the 
spleen .27-29 This response could be elicited by re-
lease of soluble antigens , emigration of donor 
(hamster) hematolymphoid cells , or both. The "sen-
sitizing potential" of passenger leukocytes from he-
patic or cardiac allografts has recently been sug-
gested .23.30 It should be noted, however, that the 
migratory donor cells lodged first in the periphery of 
the PALS, but the earliest evidence of proliferation 
was detected in the MZ. 
The relative ability of soluble or particulate non-
cellular xenoantigens to elicit MZ splenocyte prolif-
eration, the need for accessory cell processing, 
and/or T- cell help for xenoantigens cannot be di-
rectly determined from this study. However, the 
splenic proliferative activity appears to be at least 
partially T-cell dependent, since FK506 markedly di-
minishes it, but does not abolish it. Nevertheless, 
the location and phenotypic profile of the respond-
ing recipient splenocytes suggest that a subpopula-
tion of B cells that mediate T-independent B-cell im-
munity31 are probably involved. 
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Table 1. Flow Cylomelric A nalysis of Splenoc)!tes 4 Days after Hepatic Xenografting from Recipients without and with 
FK506 Therapy Compa red wilh Normal Controls 
Blasts/total splenocytes (%) 
Untreated 
reCipients (n = 3) 
34 
FK506-treated 
recipients (n = 2) 
18 
Normal LEW rat 
(n = 3) 
<2 
Blast phenotype 
(% of blasts) 
Normal size lymphocyte 
phenotype (% of total) 
IgM""gt'I/lgDdUIl 
IgMd""/lgDDro911' 
W3/25+ 
48 25 12 
20 27 30 
18 24 41 
OX8+ 10 16 17 
NKR-P1+ 6 2 25 
Figure 7. Hamster cells (g rel?n .fluorescent) were deteclable in Ihe 
PALS alld MZ of the rat spleen one day afier lransplanlalion (anli-
harnsler IF X 250) Similar cells were difficult 10 deteel in cardiac xe-
>1o[!,rafi recipienl, arid were abse"l by day 5. 
This same sub population of 8 cells forms the 
host's primitive defense against blood-borne 
polysaccharide antigens, such as those encoun-
tered on bacteria and bacterial products like 
lipopolysaccharide.32-38 We are unsure whether the 
red pulp 8 cells represent a later maturational 
phase of those in the MZ, since the relationship be-
tween the two, if any, is currently unknown33-39 
However, it is tempting to speculate that spleniC 
IgM++/lgO+ 8 cells are the rat analog of human 
C05+ 8 cells and mouse Ly 1 + 8 cells. 33-39 These 
8-cell populations, along with natural killer cells, are 
thought to represent an earlier evolutionary stage of 
the immune system designed to provide broad-
spectrum recognition of harmful foreign materials32 
It is not unreasonable to suggest that rat IgM++/ 
IgO+ splenic 8 cells are the source of the destruc-
tive xenoreactive antibodies in this model. 8ach et 
al 40 have also suggested that 81 (C05+) cells may 
be the source of xenoreactive antibodies, based on 
their polyreactive nature 41 
We tested the importance of IgM+ +(brlght)/ 
IgO+(dull) 8 cells in xenograft rejection using a sin-
gle 500 mg/m2 intraperitoneal dose of CYP, which 
selectively ablates this splenic 8-cell popula-
NORMAL 
,. /!:Z)V 
.. 2ft} IgM ~yi:i1 £li -{ ~ I~Dy 01 61{-
IgD 
10 DAYS POST 
". CYCLOPHOSPHAMIDE 
U 
0 
.. 
IgM 
1 .. 
19D 
tion.22,38 Although GYP kills all dividing cells, in-
cluding other lymphocytes, 10 days after a single 
injection the T-cell zones and IgO+ B cells are re-
plenished, whereas the MZ IgM++/lgO+ cells are 
still markedly depleted.22 
Lastly, preliminary studies in nude rats, which are 
T cell deficient but retain this fully functioning B-cell 
population,39 find that they are able to reject car-
diac xenografts in the normal fashion.42 Liver xe-
nograft rejection is only slightly delayed in these an-
imals, except after splenectomy, in which case 
100% of cardiac and 40% of hepatic grafts are ac-
cepted long term without therapy (LA Valdivia, per-
sonal communication). Examination of the nude 
rats3 spleens after hepatic or cardiac xenografts 
confirmed the persistence of these B cells and their 
participation in xenograft rejection (unpublished ob-
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4 DAYS POST-HEPATIC 
7 XENOTRANSPLANTATION 
IgM 
llV 1'J 
IgD 
Figure 8. In a normal rat .Ipleen, 12% of splenocytes are IgM"rig}"/IgIYull 
(top left), hut even 10 days after a single injection ofCYP, this population is 
reduced to <2% (bottom left). Four days after hepatic xenograjiing without 
treatment, 48% of the blastic splenoc)'tes are IgM"r<,h'iIgUiull (top right). in-
dicating the marked stimulation oltbis population. 
servation). Overall, the evidence provided herein, 
combined with other published stud-
ies,9,1o,12.15,42,43 suggests that splenic IgM++/lgO+ 
B cells play an important effector function in 
hamster-to-rat xenograft rejection. 
Nevertheless, the GYP protocol used in this 
study, like splenectomy, when used alone was un-
able to sufficiently control the T cell-mediated graft 
damage, so that examination of the rejected cardiac 
grafts in these recipients showed a heavy lympho-
cytic infiltrate. The addition of FK506 to GYP, how-
ever, resulted in excellent xenograft survival. Pre-
sumably this therapeutic regimen controls both 
arms of the immune system, as has been shown by 
Murase et al9 and Hasan et ai, 10 who suggested a 
direct role for the "natural" antibodies in graft rejec-
tion,lO 
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Table 2. Surviual Results of Heart and Liver Xenograft 
Recipients Treated with C)'C/opbosphamide Gil'en 
as a Single Agent 10 Days befi!re Surgery or in 
Combination with FK506 
CYP 
Xenograft 80 mg/kg 
type* day -10 FK506 Survival (days)t 
HTX 3,3,3,3 
HTX + 6,6,6,6,7 
HTX + 3,3,3,3,4 
HTX + + >74,t >74, >68, >68, >66 
OLT 6,7,7,7,8 
OLT + 6,7,8,8,9 
OLT + 27,33,48,66,102,164 
OLT + + >65, >66, >66, >66 
* HTX, heart xenografts; OlT, liver xenografts. 
t The survival days in bold type represent cessation of graft 
heart beat in the cardiac heart reCipients and death in the liver re-
cipients, 
+ > means that the animal is still surviving after the indicated 
number of days. 
The tremendous advantage of a dual pharma-
ceutical approach to optimal control of allograft re-
jeclion, as well as the ability of CYP to inhibit arterial 
fibrinoid necrosis in renal allografts (a humoral in-
sult), was first shown by Starzl et aI. 44- 4 ? This lesson 
has also been the conclusion of several experimen-
tal xenograft models 5 ,g, 10, 1214.42.43.48 In our experi-
ence, FK506 has been the most Important drug for 
xenotransplantation,89 presumably because of its 
effect on T cells, which indirectly also mutes the 
8-cell response, However, FK506 alone was ineffec-
tive in the cardiac model. In the liver model, FK506 
alone increased survival, but the majority of recipi-
ents suffered late graft failure from biliary obstruc-
tion, We consider this late complication to be a de-
layed manifestation of earlier humoral injury to the 
biliary tree 49 
If many of the "natural" antibodies, which are now 
a barrier to xenotransplantation, are shown to arise 
from this primitive 8-cell popUlation, more selective 
and less toxic treatment strategies can be de-
signed. Once the primitive host defense mecha-
nisms have been overcome, antibody accommoda-
tion? may permit recovery of this 8-cell system and 
protection against common bacterial pathogens, 
without graft damage 9 In addition, Murase et al50 
have recently shown the establishment of micro-
chimerism after hepatic xenotransplantation, which 
may offer some degree of long term protection 
against xenograft rejection, 
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